MétaCan
Menu
← Back to cohort

Thalidomide +/− Corticosteroids for the Treatment of Multiple Myeloma Patients ≥ 70 Years of Age.

2004· article· en· W2595668491 on OpenAlexaff
Donna Reece, Christine Chen, Suzanne Trudel, Joseph Mıkhael, Hong Chang, A. Keith Stewart

Bibliographic record

VenueBlood · 2004
Typearticle
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsPrincess Margaret Cancer CentreUniversity Health Network
Fundersnot available
KeywordsMedicineThalidomidePrednisoneGastroenterologyInternal medicineLenalidomideThrombocytosisMultiple myelomaSurgeryPlatelet

Abstract

fetched live from OpenAlex

Abstract Between September 2000 and July 2004, 33 multiple myeloma (MM) patients (pts) ≥ 70 years of age were treated with thalidomide (THAL) alone (4 pts) or THAL plus corticosteroids (CS) (29 pts). Two were treated at diagnosis while 31 received THAL +/− CS after a median of 2 (range 1–5) prior regimens. Prophylactic anticoagulation was not routinely given. In most pts, the THAL dose was slowly increased as tolerated to a maximum of 200 mg/day. Initial CS therapy was pulse dexamethasone (DEX) in 14 and prednisone 50–100 mg every 2 days in 15 pts; in 4, the DEX dose was reduced or changed to prednisone when responses were noted and/or CS toxicity was encountered. Median age was 73 (range 70–88) yrs; median beta2-microglobulin level was 403 (range 153–2120) nmol/L and CRP level 4 (range 1–91) mg/L at referral. MM subtype was IgG kappa:lambda (8:12 pts), IgA kappa:lambda (6:4 pts), light chain kappa:lambda (1:1 pts) and IgD kappa (1pt). Initial stage was IIIA:B in 20:5, IIA:B in 3:1 and IA in 4 pts. Cytogenetic studies were available in 11, of whom 1 had t(4;14), 2 complex changes, 1 monosomy 7 and 1 other abnormalities. Eighteen pts had significant cardiac disease, 3 vascular disease and 4 diabetes at the time therapy was initiated. Four had other hematological malignancies noted before/shortly after THAL +/− CS was started, including MDS in 2, essential thrombocytosis in 1 and AML in 1. The median maximum dose of THAL was 150 (range 50–400) mg and the median duration of therapy was 7 (1.5–19+) mos. To date, 14 (42%) pts have achieved PR and 5 (15%) MR; four (12%) experienced stable disease. The median duration of response was 7 (range 1.5–23+) mos. Fatigue/sleepiness (5), syncope (2), peripheral neuropathy (4) and other reasons (4) necessitated THAL dose reductions in 15 pts; 7 pts stopped THAL due to toxicity. Two TIAs and 1 DVT were observed; 2 of these pts received appropriate medical therapy and continued THAL without further vascular complications. No treatment-related deaths occurred. Eleven of 33 (33%) remain on THAL +/−CS. The actuarial overall survival rate was 80% at 1 year and 55% at 2 yrs after starting THAL +/− CS therapy, while the progression-free survival rate was 42% and 20% at 1 and 2 yrs, respectively. We conclude: 1) THAL +/−CS can be given safely in elderly MM pts, although dose reductions are usually needed; 2) MM response/stabilization was achieved in 69%; 3) THAL +/− CS therapy offers a median benefit of 7 mos in poor prognosis elderly MM pts.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.031
GPT teacher head0.296
Teacher spread0.265 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2004
Admission routes1
Has abstractyes

Explore more

Same venueBlood→Same topicMultiple Myeloma Research and Treatments→French-language works237,207→